| Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013 | 4112 | 2013 |
| MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer P Ji, S Diederichs, W Wang, S Böing, R Metzger, PM Schneider, N Tidow, ... Oncogene 22 (39), 8031-8041, 2003 | 2591 | 2003 |
| Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... New England Journal of Medicine 370 (13), 1189-1197, 2014 | 1859 | 2014 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy … EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ... The Lancet 384 (9944), 665-673, 2014 | 1462 | 2014 |
| Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) AK Kakkar, MN Levine, Z Kadziola, NR Lemoine, V Low, HK Patel, ... Journal of Clinical Oncology 22 (10), 1944-1948, 2004 | 902 | 2004 |
| Early palliative care for adults with advanced cancer MW Haun, S Estel, G Rücker, HC Friederich, M Villalobos, M Thomas, ... Cochrane Database of Systematic Reviews, 2017 | 860 | 2017 |
| Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, ... New England Journal of Medicine 383 (10), 944-957, 2020 | 832 | 2020 |
| Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non … L Paz-Ares, F de Marinis, M Dediu, M Thomas, JL Pujol, P Bidoli, ... The lancet oncology 13 (3), 247-255, 2012 | 789 | 2012 |
| Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers S Diederich, D Wormanns, M Semik, M Thomas, H Lenzen, N Roos, ... Radiology 222 (3), 773-781, 2002 | 768 | 2002 |
| PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin … LG Paz-Ares, F de Marinis, M Dediu, M Thomas, JL Pujol, P Bidoli, ... Journal of clinical oncology 31 (23), 2895-2902, 2013 | 752 | 2013 |
| The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma … A Warth, T Muley, M Meister, A Stenzinger, M Thomas, P Schirmacher, ... Journal of clinical oncology 30 (13), 1438-1446, 2012 | 724 | 2012 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 570 | 2018 |
| Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer M Reck, A Luft, A Szczesna, L Havel, SW Kim, W Akerley, MC Pietanza, ... Journal of Clinical Oncology 34 (31), 3740-3748, 2016 | 547 | 2016 |
| Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... The lancet oncology 17 (4), 452-463, 2016 | 514 | 2016 |
| Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non–small-cell lung cancer G Scagliotti, S Novello, J von Pawel, M Reck, JR Pereira, M Thomas, ... Journal of Clinical Oncology 28 (11), 1835-1842, 2010 | 514 | 2010 |
| When do we need to care about the caregiver? Supportive care needs, anxiety, and depression among informal caregivers of patients with cancer and cancer survivors H Sklenarova, A Krümpelmann, MW Haun, HC Friederich, J Huber, ... Cancer 121 (9), 1513-1519, 2015 | 500 | 2015 |
| Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer M Thomas, C Rübe, P Hoffknecht, HN Macha, L Freitag, A Linder, ... The lancet oncology 9 (7), 636-648, 2008 | 393 | 2008 |
| Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ... The lancet oncology 22 (7), 959-969, 2021 | 373 | 2021 |
| Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop R Pirker, FJF Herth, KM Kerr, M Filipits, M Taron, D Gandara, FR Hirsch, ... Journal of Thoracic Oncology 5 (10), 1706-1713, 2010 | 358 | 2010 |
| Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. JD Hainsworth, HA Burris 3rd, JB Erland, M Thomas, FA Greco Journal of clinical oncology 16 (6), 2164-2168, 1998 | 329 | 1998 |
